Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

A new trial shows Eli Lilly’s daily pill orforglipron can cut body weight by up to 20% in adults with obesity, offering a ...

Novo NordiskNVO stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight ...

It’s unclear how much such a pill would cost, but Novo Nordisk’s Ozempic and Wegovy shots currently go for several hundred ...

Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say. Eli Lilly may have to fight hard to keep its ...

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide pill led to "significant weight loss" in a trial.

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

An IQVIA report published earlier this year found that 43% of anti-obesity assets currently in development are orally ...

A new type of weight loss jab can help maintain weight reductions by tackling the underlying causes of obesity, scientists ...